Register for our free email digests:
Are you sure you'd like to remove this alert? You will no longer receive email updates about this topic.
Hearings in July and the fall will follow, but if the first session was any indication, industry doesn't have anything to worry about.
Latest From Pricing Debate
Tomas Philipson, a University of Chicago professor and consultant to the pharmaceutical industry, is named to the White House Council of Economic Advisors.
The US president made what seemed to be a retaliatory statement about high drug prices after Merck CEO Ken Frazier resigned from his jobs council.
Pooled procurement will not fix problems relating to affordability and access to medicines in South America, says the US pharma industry association, PhRMA, in response to news that Mercosur trade bloc members will join forces to negotiate better prices for medicines.
Company says that while FDA has focused on expediting approval of third and fourth generics, it has not done so for first generics and complex products.
Another alliance among EU countries to tackle high medicines prices is gathering pace. Eight countries are to soon start swapping pricing information and have agreed to join forces to negotiate more affordable prices.
News that premiums will be lower in 2018 aligns with President Trump's concern with lowering drug costs, Administration officials announce.
Nine new approved treatments that have faced delays in getting to Irish patients should hit the market this year, says the Health Service Executive. The innovative pharmaceutical industry welcomes the move but is calling for clear political direction on future processes.
Regeneron’s Eylea is the new holder of the number one spot in Medicare Part B prescription drug payments. It is also the fastest growing entrant on the top-ten list tracked by MedPAC. That is a sign of great commercial success – but could be an uncomfortable spotlight.
Roche has praised the flexibility of the UK’s Cancer Drugs Fund, but says NICE cost-effectiveness analysis would be unnecessary if industry rebates fed into a UK drugs budget.
You must sign in to use this functionality
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
Please Note: Only individuals with an active subscription will be able to access the full article. All other readers will be directed to the abstract and would need to subscribe.